Tofacitinib, bir oral Janus kinaz inhibitörü: romatoid artrit klinik gelişim programı genelinde malignitelerin analizi
Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-205847. doi: 10.1136/annrheumdis-2014-205847. [Epub ahead of print]
The developments of certain malignancies associated with chronic inflammatory diseases such as RA is known to occur to a greater extent than that of the general population. It is also know that certain RA treatments can affect malignancy rates. As such, newer immunomodulatory agents, such as the JAK inhibitor tofacitinib, are closely monitored for safety events of special interest, including malignancies.
This paper analyses pooled malignancy data from the tofacitinib RA clinical develop...
This paper analyses pooled malignancy data from the tofacitinib RA clinical develop...